Q&A with Vadim Alexandre Head of Research at Northland Capital Partners
19th January 2017
Northland Capital Partners’ Vadim Alexandre discusses Evgen Pharma PLC in this exclusive interview with DirectorsTalk
Northland Capital Partners’ Vadim Alexandre discusses Evgen Pharma PLC in this exclusive interview with DirectorsTalk
Evgen Pharma Plc (LON:EVG) are the topic of conversation with Northland Capital Partners head of Research Vadim Alexandre. Vadim explains the importance of news that a first patient has been
Northland Capital partners view on Evgen Pharma PLC LON:EVG: First Patient Dosing in this trial represents another major milestone for Evgen. With two Phase 2 trials now dosing patients and
Dr Stephen Franklin, CEO of Evgen Pharma LON:EVG, commented: “The first patient being dosed in this Phase II trial of SFX-01 in breast cancer is another major milestone for Evgen
Evgen Pharma LON:EVG a clinical stage drug development company focused on cancer and neurological conditions, yesterday announced that it has received a positive interim safety review from the independent Data
Dr Stephen Franklin, CEO of Evgen Pharma LON:EVG, commented: “We are delighted that the DSMB has given a favourable review of our Phase II study of SFX-01 in subarachnoid haemorrhage,
Evgen Pharma plc (LON:EVG) is a virtual pharmaceutical company focused on the development of a synthetic version of sulforaphane, which is known to modulate key signalling pathways involved in cellular
Evgen Pharma’s Dr Stephen Franklin discusses the phase II trials of their lead drug SFX-01 in this exclusive interview with DirectorsTalk
Evgen Pharma Plc (LON:EVG) CEO Dr Stephen Franklin talks to DirectorsTalk about it’s latest interim statement. Stephen reminds us what SFX-01 is and what diseases they are targeting, runs through
Evgen Pharma plc (AIM: EVG), the clinical stage drug development company focused on cancer and neurological conditions, has given DirectorsTalk its unaudited interim results for the six months ended 30
© 2024 – DirectorsTalk. All rights reserved. Reproduction in whole or in part, in any form or medium without express written permission is prohibited.
